

## Prehospital Stroke: Minimum, Preferred, and Optional Dataset Recommendations.

Dataset	Minimal	Preferred	Optional
<b>Demographics</b>	<ul style="list-style-type: none"> <li>Age</li> <li>Sex</li> </ul>		<ul style="list-style-type: none"> <li>Ethnicity</li> </ul>
<b>Index event &amp; Baseline function</b>	<ul style="list-style-type: none"> <li>Interval from stroke onset to review</li> <li>Stroke of known onset (yes/no)</li> <li>Baseline (first measured) BP</li> <li>Baseline glucose</li> <li>Baseline NIHSS (total score)</li> </ul>	<ul style="list-style-type: none"> <li>Prehospital scale score</li> <li>Pre-morbid mRS</li> <li>TOAST<sup>1</sup> classification</li> </ul>	
<b>Acute Interventions</b>	<ul style="list-style-type: none"> <li>IVT</li> <li>EVT</li> <li>Blood pressure lowering agents administered (yes or no) in the hyperacute phase</li> <li>Oral anticoagulant reversal agents administered in the hyperacute phase (specify agents used)</li> </ul>		
<b>Medical History</b>	<ul style="list-style-type: none"> <li>AF</li> </ul>	<ul style="list-style-type: none"> <li>Hypertension</li> <li>Diabetes Mellitus</li> <li>Prior history of coronary artery disease</li> <li>AF on first ECG</li> <li>AFDAS<sup>2</sup></li> </ul>	<ul style="list-style-type: none"> <li>Hyperlipidaemia</li> <li>Smoking status</li> <li>Alcohol intake (g/week)</li> </ul>
<b>Baseline Imaging†</b>	<ul style="list-style-type: none"> <li>Brain imaging performed (CT/MRI)</li> <li>Vascular imaging performed (CTA/MRA)</li> <li>LVO</li> <li>MeVO/DVO<sup>3</sup></li> </ul>	<ul style="list-style-type: none"> <li>Infarct volume</li> <li>Haematoma volume</li> <li>ASPECTS Score<sup>4</sup></li> <li>Estimated core volume on perfusion imaging<sup>5</sup></li> </ul>	
<b>Baseline Laboratory Variables</b>		<ul style="list-style-type: none"> <li>Haemoglobin</li> <li>Troponin T or troponin I</li> <li>eGFR</li> <li>LDL</li> </ul>	
<b>Outcomes*</b>	<ul style="list-style-type: none"> <li>Final diagnosis (TIA, IS, ICH, or stroke mimic)</li> <li>Death (in-hospital)</li> </ul>	<ul style="list-style-type: none"> <li>Functional outcome (mRS at 90 days)</li> <li>Post-stroke neurological complications (malignant oedema, haemorrhagic transformation)</li> <li>Post-stroke systemic complications (eg. post-stroke pneumonia, VTE, acute decompensated heart failure)</li> </ul>	<ul style="list-style-type: none"> <li>Recurrent stroke during follow-up</li> <li>MACE‡ during follow-up</li> </ul>
<b>Biomarker-specific data</b>	<ul style="list-style-type: none"> <li>Duration of biomarker measurement</li> </ul>		

The interval from index event to biomarker measurement is considered as a minimum item of information. †The imaging modality in all instances should be captured. \*For each outcome, the time interval between index event and outcome should be reported. ‡ It is recommended that MACE should always at a minimum include the individual components of 3-point MACE: recurrent non-fatal stroke (ischaemic or ICH), non-fatal myocardial infarction, and cardiovascular death. AF, atrial fibrillation; AFDAS, atrial fibrillation detected after stroke; ASPECTS, Alberta Stroke Program Early CT Score; CT, computerised tomography; CTA, computerised tomography angiography; DVO, distal vessel occlusion; ECG, electrocardiography; eGFR, estimated glomerular filtration rate; EVT, endovascular therapy; IS, ischaemic stroke; IVT, intravenous thrombolysis; LDL, low density lipoprotein; LVO, large vessel occlusion; MACE, major adverse cardiovascular and cerebrovascular events; MeVO, medium vessel occlusion; MRI, magnetic resonance imaging; mRS, modified Rankin scale; MRA, magnetic resonance angiography; NIHSS, National Institute for Health Stroke Scale; TIA, transient ischaemic attack; TOAST, The Trial of Org 10172 in Acute Stroke Treatment; VTE, Venous thromboembolism.

